Literature DB >> 18288993

Post-translational modifications of nuclear co-repressor RIP140: a therapeutic target for metabolic diseases.

M D Mostaqul Huq1, Pawan Gupta, Li-Na Wei.   

Abstract

Most proteins undergo post-translational modification (PTM), which is known to play roles in normal physiological processes and the progression of many diseases. In this review, we summarized and discussed the mass spectrometry (MS)-based studies of various PTMs of nuclear co-repressor, receptor interacting protein 140 (RIP140), as well as the significance of these PTMs in modulating the biological activities of RIP140, specifically in adipocytes. Comprehensive analyses of RIP140 by MS identified specific sites of PTMs on RIP140, including that of phosphorylation, acetylation, pyridoxylation, and protein arginine methylation. Studies of these PTMs revealed their combinatorial effects on the activities of RIP140 with respect to the regulation of hormone target genes and fat accumulation in adipocytes. These proteomic studies have presented evidence for the biological significance of specific PTMs of RIP140, and uncovered nutritional and physiological factors that trigger these PTMs in adipocytes. This could provide insights into potential, new therapeutic targets for diseases concerning adipocytes such as metabolic disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18288993     DOI: 10.2174/092986708783497382

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  29 in total

1.  Cholesterol regulation of receptor-interacting protein 140 via microRNA-33 in inflammatory cytokine production.

Authors:  Ping-Chih Ho; Kun-Che Chang; Ya-Shan Chuang; Li-Na Wei
Journal:  FASEB J       Date:  2011-02-01       Impact factor: 5.191

Review 2.  Biological activities of receptor-interacting protein 140 in adipocytes and metabolic diseases.

Authors:  Ping-Chih Ho; Li-Na Wei
Journal:  Curr Diabetes Rev       Date:  2012-11

3.  Endothelin-1 promotes cytoplasmic accumulation of RIP140 through a ET(A)-PLCβ-PKCε pathway.

Authors:  Ping-Chih Ho; Yao-Chen Tsui; Yi-Wei Lin; Shawna D Persaud; Li-Na Wei
Journal:  Mol Cell Endocrinol       Date:  2011-12-19       Impact factor: 4.102

4.  Gene repressive activity of RIP140 through direct interaction with CDK8.

Authors:  Shawna D Persaud; Wei-Hong Huang; Sung Wook Park; Li-Na Wei
Journal:  Mol Endocrinol       Date:  2011-08-25

5.  RIP140 contributes to foam cell formation and atherosclerosis by regulating cholesterol homeostasis in macrophages.

Authors:  Yi-Wei Lin; Pu-Ste Liu; Neeta Adhikari; Jennifer L Hall; Li-Na Wei
Journal:  J Mol Cell Cardiol       Date:  2014-12-18       Impact factor: 5.000

6.  A negative regulatory pathway of GLUT4 trafficking in adipocyte: new function of RIP140 in the cytoplasm via AS160.

Authors:  Ping-Chih Ho; Yi-Wei Lin; Yao-Chen Tsui; Pawan Gupta; Li-Na Wei
Journal:  Cell Metab       Date:  2009-12       Impact factor: 27.287

7.  Receptor-Interacting Protein 140 Orchestrates the Dynamics of Macrophage M1/M2 Polarization.

Authors:  Yi-Wei Lin; Bomi Lee; Pu-Ste Liu; Li-Na Wei
Journal:  J Innate Immun       Date:  2015-07-23       Impact factor: 7.349

Review 8.  Overflow phenomenon in serum lutein after supplementation: a systematic review supported with SNPs analyses.

Authors:  Abdulrahman M Alharbi; Mohammed A Kilani; Tos Tjm Berendschot
Journal:  Int J Ophthalmol       Date:  2021-07-18       Impact factor: 1.779

9.  Retinoic acid mediates long-paced oscillations in retinoid receptor activity: evidence for a potential role for RIP140.

Authors:  Kelly C Heim; Joshua J Gamsby; Mary P Hever; Sarah J Freemantle; Jennifer J Loros; Jay C Dunlap; Michael J Spinella
Journal:  PLoS One       Date:  2009-10-28       Impact factor: 3.240

10.  RIP140 in thyroid hormone-repression and chromatin remodeling of Crabp1 gene during adipocyte differentiation.

Authors:  Sung Wook Park; Wei-Hong Huang; Shawna D Persaud; Li-Na Wei
Journal:  Nucleic Acids Res       Date:  2009-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.